IMC-002

IMC-002 is a monoclonal antibody (fully human IgG1) from ImmuneOncia Therapeutics. An anti-CD47 antibody that blocks CD47 binding to SIRP-alpha so macrophages engulf cancer cells; the company says its affinity is tuned to avoid binding red blood cells. Its furthest stage is phase 1, for advanced solid tumours and lymphoma. ClinicalTrials.gov registers it in 2 studies linked below. Whether it works in people has not been established unless a trial below reports it.